The use of psychedelics as medicine has opened up a new industry growing exponentially at a rapid pace
As attitudes shift we are witnessing a rise in academic research clinical trials and commercial investment
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save US$1 trillion on lost productivity disrupting the way we approach healthcare
We highlight key psychedelic players, innovations and milestones, providing trustworthy insights to help investors cut through the noise and identify real opportunities.
We provide perspective on the societal impacts of modernising regulations and improving access to psychedelics, revealing the real cost-benefit of collective mental healing.
We connect operators to a qualified investor audience, with access to the capital that supports industry growth and enables companies to achieve their goals.
Interested in partnering with PSYCH, media opportunities or speaking at the next event? Send us your information and thoughts on how we can collaborate.